Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma

Tumor Biology

Volumn 36, Issue 4, 2015, Pages 2257-2261

  Zhang, Jinyan ^a   Huang, Tao ^b   Zhang, Fan ^a   Xu, Junming ^a   Chen, Guoqing ^a   Wang, Xiaoliang ^a   Huang, Li ^a   Peng, Zhihai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Carbohydrate antigen 19 9; Hepatocellular carcinoma; Overall survival

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; AGED; BLOOD; CANCER STAGING; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CA-19-9 ANTIGEN; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 84936751820     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2435-6     Document Type: Article

References (28)

1. Li G, Zheng Z. Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma. Tumor Biol. 2013;34(3):1589–94.
2. Breuhahn K, Gores G, Schirmacher P. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology. 2011;53(6):2112–21.
3. Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, et al. Hepatitis b and c virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011;21(6):401–16.
4. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48(6):2047–63.
5. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol. 2011;29(29):3892–9.
6. Li W, Cai HX, Ge XM, Li K, Xu WD, Shi WH. Prognostic significance of BMP7 as an oncogene in hepatocellular carcinoma. Tumor Biol. 2013;34(2):669–74.
7. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010;61(1):317–28.
8. Galli C, Basso D, Plebani M. Ca 19-9: handle with care. Clin Chem Lab Med. 2013;51(7):1369–83.
9. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (ca 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266–70.
10. John AR, Haghighi KS, Taniere P, Esmat ME, Tan YM, Bramhall SR. Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis? Dig Surg. 2006;23(5–6):319–24.
11. Zhang S, Chen Y, Zhu Z, Ding Y, Ren S, Zuo Y. Differential expression of carbohydrate antigen 19-9 in human colorectal cancer: a comparison with colon and rectal cancers. Mol Clin Oncol. 2013;1(6):1072–8.
12. Mohri Y, Tanaka K, Ohi M, Saigusa S, Yasuda H, Toiyama Y, et al. Identification of prognostic factors and surgical indications for metastatic gastric cancer. BMC Cancer. 2014;14(6):409.
13. Tsuji M, Kashihara T, Terada N, Mori H. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, ca19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol Int. 1999;49(4):310–7.
14. Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol. 2009;16(3):623–9.
15. Pissaia Jr A, Bernard D, Scatton O, Soubrane O, Conti F, Calmus Y. Significance of serum tumor markers carcinoembryonic antigen, ca 19-9, ca 125, and ca 15-3 in pre-orthotopic liver transplantation evaluation. Transplant Proc. 2009;41(2):682–4.
16. Tao LY, Cai L, He XD, Liu W, Qu Q. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg. 2010;76(11):1210–3.
17. Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumor Biol. 2013;34(6):3279–92.
18. Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer. 2013;119(2):285–92.
19. Narita Y, Taniguchi H, Komori A, Nitta S, Yamaguchi K, Kondo C, et al. Ca19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy. Cancer Chemother Pharmacol. 2014;73(2):409–16.
20. Liu SL, Song ZF, Hu QG, Shan D, Hu SB, Li J, et al. Serum carbohydrate antigen (ca) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis. Front Med China. 2010;4(4):457–62.
21. Xiao J, He X, Wang Z, Hu J, Sun F, Qi F, et al. Serum carbohydrate antigen 19-9 and prognosis of patients with gastric cancer. Tumour Biol. 2014;35(2):1331–4.
22. Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117(19):4475–83.
23. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140(5):1410–26.
24. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140(5):1501–12.
25. Zhou H, Huang H, Shi J, Zhao Y, Dong Q, Jia H, et al. Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis b-related hepatocellular carcinoma after curative resection. Gut. 2010;59(12):1699–708.
26. Zhao YM, Wang L, Dai Z, Wang DD, Hei ZY, Zhang N, et al. Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma. Int J Cancer. 2011;129(10):2463–72.
27. Ding T, Xu J, Zhang Y, Guo RP, Wu WC, Zhang SD, et al. Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection. Cancer. 2011;117(21):4878–89.
28. Zhou L, Zhang N, Li QJ, Sun W, Zhang Y, Wang DS, et al. Association between high levels of notch 1 expression and high invasion and poor overall survival in hepatocellular carcinoma. Tumor Biol. 2013;34(1):543–53.